STTK NASDAQ
Credit Risk of going bust: lower than 74% of companies Debt: 0.5% of company value Bonds: none of note held by US funds details ▾
If the stock fell to about $0.00 (down more than 99.9%), Shattuck Labs, Inc. would be worth roughly what it owes.
Total debt $2.7M against a stock market value of $579.1M.
Distance to default 8.22 (Merton model): prices to 2026-10-27, balance sheet 2026-06-30, debt counted $900K (short-term plus half of long-term), stock volatility 75.8%; Altman Z'' 20.97. A ranking and a back-test, not a forecast.
US fund filings (SEC N-PORT) show under $25M of this company's bonds, so there is no bond page. Its debt may be bank loans or privately placed. How these are computed.
Austin, TX 78701
US
Shattuck Labs, Inc. operates as a biotechnology firm based in the United States, currently at the clinical development stage. Its core mission is to create innovative therapeutics designed to combat both cancer and autoimmune diseases. The company's leading experimental compound, SL-172154, is presently undergoing Phase 1 clinical assessment for the treatment of ovarian, fallopian tube, and peritoneal cancers. Furthermore, Shattuck Labs is advancing another product candidate, SL-279252, which is also in Phase 1 trials for patients afflicted with advanced solid tumors and lymphoma. Established in 2016, the company maintains its corporate headquarters in Austin, Texas.
Recent Insider Trades
| Name | Type | Shares | Price | Date |
|---|---|---|---|---|
| Shukla Abhinav A. | M-Exempt | 12,153 | $3.57 | 2026-07-06 |
| Shukla Abhinav A. | M-Exempt | 12,153 | $3.57 | 2026-07-06 |
| Shukla Abhinav A. | M-Exempt | 410 | $3.57 | 2026-07-02 |
| Shukla Abhinav A. | S-Sale | 410 | $7.01 | 2026-07-02 |
| Shukla Abhinav A. | M-Exempt | 410 | $3.57 | 2026-07-02 |